Exploratory Clinical Study of Apatinib and PD-1 in Treating Advanced Gastric Cancer

Sponsor
Henan Cancer Hospital
Study ID
NCT03954756
Phase
PHASE2
Status
Unknown

Conditions

  • Advanced Gastric Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib and PD1 — DRUG
    1. Apatinib starting dose of 500mg, qd, oral, taken half an hour after a meal 2. PD-1 was administered 200mg (3mg/kg for underweight patients) iv every 2 weeks.

Study Details

The Purpose of This Study is to Evaluate the Efficacy and Safety of Apafitini Combined With PD1 in Patients With Advanced Gastric Cancer After Second-line Treatment Failure, Thus Providing More Options for Patients With Advanced Gastric Cancer.

Key Dates

Start date
Jun 1, 2019
Status verified
May 2019
Primary completion
Jun 1, 2021
Completion
Jun 1, 2021

Study Design

Enrollment
35 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: apatinib and PD-1
    Every patients will received apatinib orally every day and PD-1 200mg (3mg/kg for underweight patients) iv every 2 weeks until disease progression or intolerance of side effect

Primary Outcome Measure

Overall survival rate [ Time Frame: up to 2 year ]

Central Contacts

Related Studies